N.V. Nutricia

The invention relates to a nutritional composition comprising a combination of (i) omega-3 fatty acid DHA with (ii) vitamin B2 and (iii) vitamin D3 and one or more from (iv) choline or a salt thereof and/or choline esters; and (v) dietary fibres and/or dietary butyrate for use in the treatment of neurodegenerative diseases and/or neurotrauma, brain injury and/or brain damage. The invention also relates to a composition comprising a combination of DHA, vitamin B2, vitamin D3 with one or more from (iv) choline or a salt thereof and/or choline esters; and (v) dietary fibres and/or dietary butyrate.

The invention provides a container for infant formula food with anti-counterfeit measures. In order to prevent counterfeiting, the container comprises a cover for closing the container. An outer scannable code is provided on the container so as to be scannable from the outside. Inside the container, a gas-tight membrane seal for sealing a food content of the container prior to use is provided. On the gas-tight membrane seal, an inner scannable code is provided so as to be only scannable after opening the container.

The invention relates to nutritional compositions for infants and in particular formulae for infants comprising human milk oligosaccharides, specific bifidobacteria, and urea as non-protein nitrogen source for improving the intestinal microbiota.

The present invention provides a process of producing a lactose concentrate, said process comprising the step of subjecting a partially demineralised aqueous lactose isolate to electrodialysis to produce a biotin-reduced lactose isolate containing at least 90% lactose by weight of dry matter and less than 2 mg ash per gram of lactose, and containing: 0.02-1.5 mg sodium per gram of lactose; 0.02-2 mg potassium per gram of lactose; 0.05-1.5 mg chloride per gram of lactose; 0.01-0.25 μg biotin per gram of lactose. The present invention also relates to a demineralised lactose concentrate having a reduced biotin content that can be produced by the aforementioned process. The invention further relates to an oligosaccharide-enriched biotin-reduced fraction that is obtained when lactose is separated before or after the electrodialysis step.

A lid structure ( 10 ) for a container ( 40 ) comprises an annular collar ( 14 ) for attachment to the container, having an opening ( 15 ) for providing access to an interior ( 56 ) of the container. The lid structure further comprises a lid ( 12 ) for closing the opening, connected to the collar by a first living hinge. The lid comprises a first lid portion and a second lid portion connected together by a second living hinge which traverses the top surface of the lid and is parallel to the first living hinge. The first lid portion covers the opening. The second lid portion comprises a mating element and the collar comprises a complementary mating element, being configured to engage together to latch the lid to the collar in the closed position of the lid, whereby latching and unlatching of the lid structure is provided by a pivotable motion of the second lid portion about the second living hinge.

The invention relates to a composition for use in regulating the autonomic nervous system.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.

The present invention relates to a nutritional composition for infants and young children comprising a digestible carbohydrate component, wherein the digestible carbohydrate component comprises a mixture of free galactose and at least one digestible carbohydrate selected from the group consisting of maltodextrin and glucose syrup, and with reduced or no lactose and glucose. The invention also relates to the use of the nutritional composition according to the invention for improving body composition or body composition development.

The invention relates to a process for dephosphorylation of skim milk, ultra-filtered milk (UF milk) or micellar casein isolate (MCI) comprising (i) acidification of a skim milk, UF milk or MCI preferably not lower than pH 6.0, preferably between 6.0 and 6.7, (ii) cooling the acidified skim milk, UF milk or MCI to the temperature between 0° C. and 15° C., (iii) adding gluconate and/or maleate to the cooled skim milk, UF milk or MCI and, (iv) washing the skim milk, UF milk or MCI, to remove phosphorus, thus dephosphorylating the skim milk, UF milk or MCI, preferably to an extent that the total phosphorous content of the skim milk, UF milk or MCI is reduced with at least 20%, preferably 20-40%, more preferably 30-40% compared to the material provided to step (i). The invention also relates to dephosphorylated MPC, MPI or MCI obtainable by the process of the invention, and to a liquid heat-sterilized enteral nutritional composition comprising 2.0-3.0 kcal/ml wherein 16-35 en % is provided by protein, the combination of caloric content and relative protein caloric content selected such that there is 10-18 g/100 ml protein, preferably 12-18 g/100 ml protein in the composition, wherein the protein comprises micellar casein (MC), whey protein (WP) and optionally caseinate (CAS), wherein there is at least 70 wt % MC and less than 15 wt % WP, based on total protein content, and wherein the composition has a total amount of phosphorous less than 192 mg/100 ml and/or 30-80 mg/100 kcal, preferably at least 30-80 mg/100 kcal, most preferably less than 192 mg/100 ml and 30-80 mg/100 kcal.